Table 1. Summary of VP tumor cohort.
| Mouse | Lifespan, days | Gross phenotype | Karyotype1 | Surface expression |
|---|---|---|---|---|
| 820 |
108 |
thy lymph |
t(2;17) (28/33) |
CD3+ TCRβ+ CD4/8 var |
| 202 |
159 |
thy lymph + spleen |
– |
– |
| 105 |
106 |
thy lymph |
– |
CD3+ TCRβ+ DP |
| 118 |
119 |
thy lymph |
t(11;15) (16/26), t(12;19) (9/26) |
CD3+ TCRβ+ DP |
| 974 |
99 |
thy lymph |
– |
CD3+ TCRβ+ CD4/8 var |
| 975 |
103 |
thy lymph |
t(12;12) (12/36), t(11;11) (15/36) |
CD3- TCRβ- DP |
| 112 |
134 |
thy lymph |
– |
CD3- TCRβ- DP |
| 979 |
102 |
thy lymph |
– |
CD3+ TCRβ+ DP |
| 977 |
119 |
thy lymph |
– |
CD3+ TCRβ+ DN |
| 124 |
176 |
thy lymph |
– |
CD3- TCRβ- DP |
| 930 |
93 |
thy lymph |
– |
– |
| 207 |
231 |
thy lymph |
aneuploid |
CD3+ TCRβ+ DP |
| 228 |
123 |
thy lymph + spleen |
– |
CD3- TCRβ- DN |
| 306 |
129 |
thy lymph |
– |
CD3+ TCRβ+ DP |
| 919 |
155 |
thy lymph |
– |
CD3+ TCRβ+ DN |
| 421 |
176 |
LN tumor |
t(12;15) (24/25) |
B220+ IgM+ Igκ+/− |
| 426 |
305 |
LN tumor |
t(6;4) (23/24) |
B220+ IgM+ Igκ- |
| 618 |
213 |
thy lymph |
– |
CD3- TCRβ- DN |
| 602 |
217 |
widely disseminated |
– |
CD3- TCRβ- DN |
| 623 |
260 |
thy lymph + spleen |
– |
CD3+ TCRβ+ CD4/8 var |
| 773 |
216 |
thy lymph |
t(4;4) (15/15), t(5;5) (14/15), t(15;17) (12/15) |
CD3- TCRβ- DN |
| 720 | 365 | none apparent | – | – |
1 For each prevalent structural aberration, numbers in parentheses indicate proportion of metaphases analyzed carrying that aberration.–Dashes indicate parameters not assessed. Abbreviations: thy lymph, thymic lymphoma; CD4/8 var, variable levels of CD4 and/or CD8 expression; DP, CD4+CD8+ double positive; DN, CD4-CD8- double negative; LN, lymph node.